Jpn J Clin Oncol:临床T3前列腺癌患者根治性前列腺切除后生化复发预测因子研究

2018-07-06 AlexYang MedSci原创

临床T3前列腺癌患者经历根治性前列腺癌切除术后,癌症控制的效果仍旧不清楚。最近,有研究人员回顾了那些经历了根治性前列腺切除的1409名患者,时间为2007年4月到2014年12月,同时也包括了210名Ct3前列腺癌患者。研究排除了9名经历新辅助激素治疗的患者和3名跟踪调查失败的患者。临床阶段由一名经验丰富的放射科医生通过术前磁共振成像来判断。研究人员利用Cox比例风险分析了生化复发的预测因子。研究

临床T3前列腺癌患者经历根治性前列腺癌切除术后,癌症控制的效果仍旧不清楚。最近,有研究人员回顾了那些经历了根治性前列腺切除的1409名患者,时间为2007年4月到2014年12月,同时也包括了210名Ct3前列腺癌患者。研究排除了9名经历新辅助激素治疗的患者和3名跟踪调查失败的患者。临床阶段由一名经验丰富的放射科医生通过术前磁共振成像来判断。研究人员利用Cox比例风险分析了生化复发的预测因子。研究总共有113名患者(57%)经历了根治性耻骨后前列腺切除,85名(43%)经历了机器辅助的的前列腺癌切除。平均跟踪调查的时间为36个月。临床阶段下降在60名(30%)患者中发生,阳性手术切缘在117名患者(59%)中鉴定到,并且在89名患者中观察到了生化复发(45%)。在多变量分析中,生化复发的独立术前预测因子在阳性活检核心中占比不小于50%(风险比(HR):2.858, P < 0.0001)且活检格林森得分不小于8(HR: 1.800, P = 0.0093)。另外,术后生化复发独立预测因子为阳性手术切缘(HR: 2.490, P = 0.0018)和精囊浸润(HR: 2.750, P < 0.0001)。

最后,研究人员指出,在Ct3前列腺癌患者中选择治疗方法时,应该考虑阳性活检核心比例和活检格林森得分。与根治性耻骨后前列腺切除治疗相比,机器辅助前列腺切除也许是一种可以灵活选择的治疗方法。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1708837, encodeId=fe831e0883757, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Sun Sep 09 03:05:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865480, encodeId=56ef186548058, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Mar 07 04:05:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310687, encodeId=b778131068e4c, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sun Jul 08 11:05:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384584, encodeId=877e13845840a, content=<a href='/topic/show?id=06e068891d4' target=_blank style='color:#2F92EE;'>#生化复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68891, encryptionId=06e068891d4, topicName=生化复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Jul 08 11:05:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586113, encodeId=6342158611387, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sun Jul 08 11:05:00 CST 2018, time=2018-07-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1708837, encodeId=fe831e0883757, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Sun Sep 09 03:05:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865480, encodeId=56ef186548058, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Mar 07 04:05:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310687, encodeId=b778131068e4c, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sun Jul 08 11:05:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384584, encodeId=877e13845840a, content=<a href='/topic/show?id=06e068891d4' target=_blank style='color:#2F92EE;'>#生化复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68891, encryptionId=06e068891d4, topicName=生化复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Jul 08 11:05:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586113, encodeId=6342158611387, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sun Jul 08 11:05:00 CST 2018, time=2018-07-08, status=1, ipAttribution=)]
    2019-03-07 minlingfeng
  3. [GetPortalCommentsPageByObjectIdResponse(id=1708837, encodeId=fe831e0883757, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Sun Sep 09 03:05:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865480, encodeId=56ef186548058, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Mar 07 04:05:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310687, encodeId=b778131068e4c, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sun Jul 08 11:05:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384584, encodeId=877e13845840a, content=<a href='/topic/show?id=06e068891d4' target=_blank style='color:#2F92EE;'>#生化复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68891, encryptionId=06e068891d4, topicName=生化复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Jul 08 11:05:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586113, encodeId=6342158611387, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sun Jul 08 11:05:00 CST 2018, time=2018-07-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1708837, encodeId=fe831e0883757, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Sun Sep 09 03:05:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865480, encodeId=56ef186548058, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Mar 07 04:05:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310687, encodeId=b778131068e4c, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sun Jul 08 11:05:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384584, encodeId=877e13845840a, content=<a href='/topic/show?id=06e068891d4' target=_blank style='color:#2F92EE;'>#生化复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68891, encryptionId=06e068891d4, topicName=生化复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Jul 08 11:05:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586113, encodeId=6342158611387, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sun Jul 08 11:05:00 CST 2018, time=2018-07-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1708837, encodeId=fe831e0883757, content=<a href='/topic/show?id=ffca32501e6' target=_blank style='color:#2F92EE;'>#前列腺切除#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32501, encryptionId=ffca32501e6, topicName=前列腺切除)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbe731571573, createdName=1249898am25暂无昵称, createdTime=Sun Sep 09 03:05:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865480, encodeId=56ef186548058, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu Mar 07 04:05:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1310687, encodeId=b778131068e4c, content=<a href='/topic/show?id=25dc1002255e' target=_blank style='color:#2F92EE;'>#预测因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100225, encryptionId=25dc1002255e, topicName=预测因子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6105386, createdName=宋威, createdTime=Sun Jul 08 11:05:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384584, encodeId=877e13845840a, content=<a href='/topic/show?id=06e068891d4' target=_blank style='color:#2F92EE;'>#生化复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68891, encryptionId=06e068891d4, topicName=生化复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Sun Jul 08 11:05:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1586113, encodeId=6342158611387, content=<a href='/topic/show?id=38f8622191b' target=_blank style='color:#2F92EE;'>#根治#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62219, encryptionId=38f8622191b, topicName=根治)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=26d917348678, createdName=jeanqiuqiu, createdTime=Sun Jul 08 11:05:00 CST 2018, time=2018-07-08, status=1, ipAttribution=)]
    2018-07-08 jeanqiuqiu

相关资讯

PLoS One:低睾丸素水平男性中,睾丸素治疗和恶性前列腺癌风险研究

低睾丸素男性中的睾丸素治疗是非常常见的,并且尽管治疗周期短,该治疗方法还是使得人们对前列腺癌(CaP)风险的增加感到担忧。最近,有研究人员调查了持续适中睾丸素治疗与恶性CaP发生之间的关系。研究包括了2002年到2011年睾丸素水平低的患者,并且进行了前列腺特异性抗原(PSA)测试;排除了那些进行睾丸素治疗、前列腺或者乳腺癌、高PSA或者前列腺活检的患者。组织学确定的发生的恶性前列腺癌或者任何前列

Cancer Causes Control:进行局部前列腺癌雄激素阻断治疗糖尿病患者的糖尿病并发症风险研究

雄激素阻断治疗(ADT)在局部前列腺癌治疗中使用逐渐增加,且与随后的长期副作用结果相关,包括糖尿病。虽然之前的研究表明了ADT能够在糖尿病患者中对血糖控制起不良作用,但它与糖尿病并发症之间的相关性还没有调查过。最近,有研究人员调查了ADT治疗与前列腺癌患者糖尿病并发症之间的相关性。研究是一个回顾性的群体研究,并且在新诊断为局部前列腺癌患者中进行,时间为1995年到2008年之间。研究群体为经历根治

NEJM:无转移生存可以作为前列腺癌新药审批的主要终点(SPARTAN研究)

2018年6月28日出版的《新英格兰医学杂志》(NEJM)上,美国食品药品管理局(FDA)药物评价及研究中心的Beaver等发表了一篇文章,介绍了FDA对于前列腺癌临床研究终点设计的特殊考量[1]。 今年较早时候,FDA批准了一种雄激素受体抑制剂阿帕鲁胺(apalutamide)用于治疗非转移性去势抵抗性前列腺癌(CRPC)患者。此次批准的基础是SPARTAN研究,这是一项随机安慰剂对照研究

Int J Oncol:PPI或可有效治疗前列腺癌

Polyphyllin I(PPI)是一种天然化合物,从巴黎鸢尾根茎中提取,用于治疗发烧和头痛。在本研究中,研究人员评估了PPI在前列腺癌(PC)细胞中的抗肿瘤活性。在低剂量下,PPI可降低PC细胞的增殖、侵袭和上皮-间充质转化(EMT)。PPI降低了对肿瘤转移至关重要的基质金属蛋白酶7(MMP7)的表达,还降低了与EMT相关的因素Snail和波形蛋白的表达。此外,PPI抑制AP-1转录活性以及A

Sci Rep:尼达尼布能够通过调节细胞周期和血管生成调控因子来抑制前列腺癌恶性肿瘤的生长

前列腺癌(PCa)是最常见的恶性肿瘤并且是美国男性中癌症致死的第二大因素。增殖细胞具有对营养和氧气更高的需求,并且刺激血管再生,而血管再生在肿瘤生长、发展和转移中具有关键的作用。因此,研究人员的在癌症上的治疗焦点就聚集到了血管再生抑制因子上,比如尼达尼布。尼达尼布通过抑制细胞增殖和肿瘤生长,展现出了杰出的抗肿瘤活性,主要是由于它对肿瘤细胞、上皮细胞和周细胞具有结合作用。最近,有研究人员在体外和体内

Int J Oncol:在前列腺癌中,重楼皂苷I能够抑制入侵和上皮-间质转化

重楼皂苷I(PPI)是一种天然的化合物,可以从巴黎多叶藻的根茎中提取获得,并且在中国已经被用来治疗发烧和头痛。最近,有研究人员评估了PPI在前列腺癌(PC)细胞中的抗肿瘤活性。研究发现,在PC洗吧中,低剂量的PPI能够减少增殖和上皮-间质转化(EMT)。PPI能够减少基质金属蛋白酶7(MMP7)的表达,该酶对肿瘤的转移非常关键。PPI同样能够减少Snail和波形蛋白的表达,上述两种物质是EMT相关